Bibliographie : Cannabinoïdes et Epilepsie

Docteur Christian SUEUR, GRECC, mars 2020.

1. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (*Medicinal cannabis*) in Mexican Children with refractory Epilepsy, *Hindawi, Neurology Research International*, 2017, ID 2985729, 5 p.
2. ALI S., SCHEFFER I.E., SADLEIR L.G. : Efficacy of cannabinoids in paediatric epilepsy, *Developmental Medicine & Child Neurology*, 2018.
   Doi : 10.1111/dmcn.14087
3. American Academy of Neurology : Medical marijuana liquid extract may bring hope for children with severe epilepsy, *American Academy of Neurology Press*, 2015.
   https://www.aan.com/PressRoom/Home/PressRelease/1364
4. AMES F.R., CRIDLAND S. : Anticonvulsivant effect of cannabidiol, *South Africa Medical Journal*, 1986, 69, 1, 14.
5. ANDERSON C.L., EVANS V.F., DeMARSE T.B., FEBO M., JOHNSON C.R., CARNEY P.R. : Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children : Current State of Research, *Journal of Pediatric Neurology*, 2017, 15, 143-150.
   Doi : 10.1055/s-0037-1598109
6. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, www.medscape.com/viewarticle/860357_print , 2016
7. ATSMON J., HEFFETZ D., DEUTSCH L. et al. : Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101 : a new formulation based on gelatin matrix pellets technology, *Clinical Pharmacology in Drug Development,* 2018, 7, (7), 751-758.
   Doi : 10.1002/cpdd.408
8. AULT A. : FDA Panel Unanimously Backs Cannabis Drug for Severe Epilepsy, *Medscape*, April 19, 2018.
   www.medscape.com/viewarticle/895465
9. BABAYEVA M., FUZAILOV M., ROZENFELD P., BASU P. : Marijuana Compounds : A Non-Conventional Therapeutic Approach to epilepsy in Children, *Journal of Addiction and Neuropharmacology*, 2014, 1, (1), 1-9.
10. BARNES G., SULLIVAN J., SEARS L., et al. : Safety and tolerability of GWP42006 (CBDV) in subjects with drug resistant epilepsy and autism, Presented at : *American Epilepsy Society Annual Meeting*, New Orleans, LA, November 30-December 4, 2018, Poster 3.288.
11. BIALER M., JOHANNESSEN S.I., LEVY R.H. et al. : Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII), *Epilepsia,* 2017, 58, 181-221.
12. BIALER M., JOHANNESSEN S.I., KOEPP M.J. et al. : Progress report on new antiepileptic drugs : a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). II. Drugs in more advanced clinical development, *Epilepsia,* 2018, 59, 1842-1866.
13. BLAIR R.E., LAXMIKANT S., DESHPANDE L.S., SOMBATI S., FALENSKI K.W., MARTIN B.R., DeLORENZO R.J. : Activation of the Cannabinoid Type-1 Receptor

Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus, *The Journal of Pharmacology and Experimental Therapeutics,* 2006, 317, (3), 1072-1078.
14. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there a potential treatment role in epilepsy ?, *Expert Opinion in Pharmacotherapy*, 2015, 16, 13, 1911-1914.
15. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Endocannabinoids and epilepsy, *Chapter 6, Cannabinoids in Neurologic and Mental Disease*, Academic Press, 2015, 125-172.
16. BONN-MILLER M.O., LOFLIN M.J.E., THOMAS B.F. et al. : Labeling accuracy of cannabidiol extracts sold online, *JAMA,* 2017, 318, 1708.
17. BRAUSER D. : FDA Approves First Cannabis Drug for Rare Forms of Epilepsy, *Medscape*, June 25, 2018. www.medscape.org/viewarticle/898510
18. BRIAN P.G., SCOTT C.B. : Animal models in epilepsy research : legacies and new directions, *Nat Neurosciences*, 2015, 18, 339-343.
19. CARLINI E.A., CUNHA J.M. : Hypnotic and antiepileptic effects of cannabidiol, *J Clin Pharmacol*, 1981, 21, 417-427.
20. CHEN K., NEU A., HOWARD A.L., FÖLDY C., ECHEGOYEN J., HILGENBERG L., SMITH M., MACKIE K., SOLTESZ I. : Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental seizures, *The Journal of Neuroscience*, 2007, 27, (1), 46-58. Doi : 10.1523/JNEUROSCI.3966-06.2007
21. CHEN K.A., FARRAR M., CARDAMONE M., GILL D. et al. : Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience, *Medical Journal of Australia,* 2018 August 13.
22. CHEN Z., BRODIE M.J., LIEW D. et al. : Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study, *JAMA Neurology,* 2018, 75, 279-286.
23. CHIU P., OLSEN D.M., BORYS H.K. et al : The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats, *Epilepsia*, 1979, 20, 365-375.
24. CILIO M.R., THIELE E.A., DEVINSKY O. : The case for assessing cannabidiol in epilepsy, *Epilepsia*, 2014, 55, 6, 787-790.
25. CITRARO R., RUSSO E., De SARRO G. et al. : CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations, *Epilepsy Research*, 2013, 106, 1-2, 74-82.
26. CONSROE P.F., WOOD G.C., BUCHSBAUM H. : Anticonvulsivant nature of marihuana smoking, *JAMA*, 1975, 234, 3, 306-307.
27. CONSROE P.F., WOLKIN A. : Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats, *J Pharmacol Exp Ther*, 1977, 201, 1, 26-32.
28. CONSROE P.F., MARTIN A., SINGH V. : Antiepileptic potential of cannabidiol analogs, *J Clin Pharmacol*, 1981, 21, 8-9, 428-436.
29. CONSROE P.F. : Brain Cannabinoid systems as targets for the therapy of neurological disorders, *Neurobiological Diseases*, 1998, 5, 534-541.
30. CUNHA J.M., CARLINI E.A., MECHOULAM R. et al. : Chronic administration of cannabidiol to healthy volunteers and epileptic patients, *Pharmacology*, 1980, 21, 3, 175-185.

31. DALE T., DOWNS J., OLSON H., BERGIN A.M., SMITH S., LEONARD H. : Cannabis for refractory epilepsy in children : a review focusing on CDKL5 Deficiency Disorder, *Epilepsy Research*, 2019, 151, 31-39.
Doi : 10.1016/j.eplepsyres.2019.02.001
32. DETYNIECHI K., LAWRENCE H. : Marijuana use in epilepsy : the myth and the reality, *Curr Neurol Neurosci Rep*, 2015, 15, 65.
33. DETYNIECKI K., HIRSCH L.J. : Cannabidiol for epilepsy : trying to see through the haze, *The Lancet*, 2016, 15, 3, 235-237.
34. DEVINSKY O., VICKREY B.G., CRAMER J. et al. : Development of the quality of life in epilepsy inventory, *Epilepsia*, 1995, 36, 1089-1104.
35. DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, *Epilepsia*, 2014, 55, 6, 791-802.
Doi : 10.1111/epi.12631
36. DEVINSKY O. : Commentary : Medical Marijuana survey & Epilepsy, *Epilepsia*, 2015, 56, 1, 7-8.
37. DEVINSKY O., MARSH E., FRIEDMAN D., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, *Lancet Neurology*, 2016, 15, 270-278.
38. DEVINSKY O., CROSS J.H., LAUX L., WRIGHT S. et al. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 21, 2011-2020.
39. DEVINSKY O., PATEL A.D., CROSS J.H. et al. : Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome, *New England Journal of Medicine,* 2018, 378, 1888-1897.
40. DEVINSKY O., PATEL A.D., THIELE E.A. et al. : Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, *Neurology,* 2018, 90, e1204-e1211.
41. DEVINSKY O., VERDUCCI C., THIELE E.A., et al. : Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes, *Epilepsy & Behavior,* 2018, 86, 131-137.
42. Di MARZO V. : The endocannabinoid system : its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation, *Pharmacological Research*, 2009, 60, 2, 77-84.
43. Dos SANTOS R.G., HALLAK J.E., LEITE J.P., ZUARDI A.W., CRIPPA J.A. : Phytocannabinoids and epilepsy, *Journal of Clinical Pharm Ther*, 2015, 40, 2, 135-143.
44. EDWARDS M., PAIGE F. : The case for medical marijuana in epilepsy, *Epilepsia*, 2014, 55, 6, 783-786.
45. ELLIOTT J., DeJEAN D., CLIFFORD T., COYLE D., POTTER B., SKIDMORE B., ALEXANDER C., REPETSKI A.E., SHUKLA V., McCOY B., WELLS G.A. : Cannabis-based products for pediatric epilepsy : a systematic review, *Epilepsia*, 2018, 1-14.
Doi : 10.1111/epi.14608
46. ELLIOTT J., DeJEAN D., CLIFFORD T., COYLE D., POTTER B., SKIDMORE B., ALEXANDER C., REPETSKI A.E., McCOY B., WELLS G.A. : Cannabis for pediatric epilepsy : protocol for a living systematic review, *Systematic Reviews*, 2018, 7, 95, 1-5.
Doi : 10.1186/s13643-018-0761-
47. ELLISON J.M., GELWAN E., OGLETREE J. : Complex partial seizure symptoms affected by marijuana abuse, *Journal of Clinical Psychiatry*, 1990, 51, 439-440.

48. FEENEY D.M. : Marihuana Use Among Epileptics, *JAMA*, 1976, 235, 11, 1105.
49. FEENEY D.M. : Marijuana and Epilepsy : paradoxical anticonvulsant effects, *Advanced Biosciences*, 1978, 22/23, 643-657.
50. FERRIE C.D., PATEL A. : Treatment of Lennox-Gastaut Syndrome (LGS), *European Journal of Paediatric Neurology*, 2009, 13, 493-504.
51. FEZZA F., MARRONE M.C., MACCARRONE M., MARINELLI S. : Distinct modulation of the endocannabinoid system upon Kainic Acid-induced invivo seizures and in vitro epileptiform bursting, *Molecular and Cellular Neuroscience*, 2014, 62, 1-9.
52. FLOREK- LUSZCZKI M., ZAGAJA M, LUSZCZKI J.J. : Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock- induced seizure model and chimney test in mice, *Epilepsy Research*, 2014, 108, 10, 1728-1733.
53. FLOREK- LUSZCZKI M., ZAGAJA M, LUSZCZKI J.J. : Influence of arachidonyl-20-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute sid-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimney test in mice, *Fundam Clin Pharmacol*, 2015, 29, 382-393.
54. FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand acess program, *Annual Meeting of the American Epilepsy Society, Seattle, December 5-9*, 2014, Abstract.
55. FRIEDMAN D., DEVINSKY O. : Cannabinoids in the Treatment of Epilepsy, *New England Journal of Medicine*, 2015, 373, 1048-1058.
56. GASTON T.E., BEBIN E.M., CUTTER G.R., et al. : Interactions between cannabidiol and commonly used antiepileptic drugs, *Epilepsia,* 2017, 58, 1586-1592.
57. GASTON T.E., SZAFLARSKI J.P. : Cannabis for the treatment of epilepsy : an update, *Current Neurology and Neuroscience Reports,* 2018, 18, (11), 73. Doi : 10.1007/s11910-018-0882-y
58. GASTON T.E., BEBIN E.M., CUTTER G.R., et al. : Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program, *Epilepsy & Behavior,* 2019, 98, 201-206.
59. GEFFREY A.L., POLLACK S.F., BRUNO P.L. et al. : Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy, *Epilepsia.* 2015, 56, 1246-1251.
60. GLOSS D., VICKREY B. : Cannabinoids for epilepsy, *Cochrane Database Systematic Review,* 2012, 6.
61. GOBIRA P.H., VILELA L.R., GONCALVES B.D., SANTOS R.P., de OLIVEIRA A.C., VIEIRA L.B., AGUIAR D.C., CRIPPA J.A., MOREIRA F.A. : Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice. Possible role of the mTOR pathway and reduction in glutamate release, *Neurotoxicology*, 2015, 50, 116-21.
Doi : 10.1016/j.neuro.2015.08.007
62. GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, *Journal of Child Neurology*, 2017, 32, 35-40.
63. GORDON E., DEVINSKY O. : Alcohol and Marijuana : Effects on Epilepsy and Use by Patients, *Epilepsia*, 2001, 42, 10, 1266-1272.

64. GOWERS W.R. : Epilepsy and Other Chronic Convulsive Diseases : Their Causes, Symptoms & Treatment, New York, NY, William Wood & Company, 1885, 223-224
65. GROSS D.W., HAMM J., ASHWORTH N.L. et al. : Marijuana use and epilepsy : prevalence in patients of a tertiary care epilepsy center, *Neurology*, 2004, 62, 2095-2097.
66. GU B., …, CARNEY P.R., PHILPOT B.D. : Cannabidiopl attenuates seizures and EEG abnormalities in Angelman syndrome model mice, *Journal of Clinical Investigation*, 2019, 129, (12), 5462-5467.
Doi : 10.1172/JCI130419
67. GUGGENHUBER S., MONORY K., LUTZ B., KLUGMANN M.M. : AAV vector-mediated overexpression of CB1 cannabinoid receptor un pyramidal neurons of the hippocampus protects against seizure-induced excitotoxicity, *PloS One*, 2010, 5, 12, 15707.
68. GUY G., WRIGHT S., MEAD A., DEVINSKY O. : Use of Cannabinoids in the treatment of Epilepsy, 2015, *Patent Application Pub : US 2016/0166515 A1*, GW Pharma Limited, Cambridge, (GB), June 2016.
69. HAUSMAN-KEDEM M., MENASCU S., KRAMER U. : Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, *Brains & Development*, 2018, 40, (7), 544-551.
Doi : 10.1016/j.braindev.2018.03.013
70. HAZEKAMP A. : The trouble with CBD oil, *Medical Cannabis Cannabinoids,* 2018, 1, 65-72.
71. HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, *Epilepsy & Behavior*, 2012, 25, 4, 563-566.
72. HESS E.J., MOODY KA, GEFFREY A.L., et al. : Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex, *Epilepsia,* 2016, 57, (10), 1617-1624.
73. HILL A.J., HILL T.D.M., WHALLEY B.J. : The Development of Cannabinoid Based Therapies for Epilepsy, *Molecular, Pharmalogical, Behavioral and Clinical Feature*, 2013, 164-24.
74. HUNTSMAN R.J., TANG-WAI R., ALCORN J., VUONG S., ACTON B., CORLEY S., LAPRAIRIE R., LYON A.W., MEIER S. et al. : Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, *Frontiers in Neurology*, 2019, Vol 10, Article 716, 1-9.
Doi : 10.3389/fneur.2019.00716
75. HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, *Epilepsy & Behaviour*, 2015, 47, 138-141.
76. JOHNSON D.D., McNEILL J.R., CRAWFORD R.D. et al. : Epileptiform seizures in domestic fowl. The anticonvulsant activity of delta 9-tetrahydrocannabinol, *Canadian Journal of Biochemistry and Physiology,* 1975, 53, 439-448.
77. JONES et al. : Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures, *Seizures*, 2012, 21, 5, 344-352.

78. KALKACH-APARICIO M., CUELLAR-HERRERA M., FLORES-RAMIREZ E.L. et al. : The use of cannabis as an antiepileptic treatment in Mexico : A review, bioethical analysis, discussion and position of the Hospital General de Mexico, Epilepsy Clinic, *Revista Médical del Hospital General de Mexico*, 2016, 11 p.
79. KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, *Pediatric Neurology*, 2017, 71, 18-23.
80. KARANIAN D.A., KARIM S.L., WOOD J.T., WILLIAMS J.S., et al. : Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain dammage, *J Pharmacol Exp Ther*, 2007, 322, 3, 1059-1066.
81. KATONA I. : Cannabis and Endocannabinoid Signaling in Epilepsy, *Handbook of Experimental Pharmacology*, 2015, 231, 285-316.
82. KOO C.M., KANG H.-C. : Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, *Journal of Epilepsy Research*, 2017, 7, 1, 1-5.
83. KOPKA M. : Cannabinoids in the treatment of epilepsy – an update review, *Journal of Epileptology*, 2019, 27.
Doi : 10.2478/joepi-2019-0004
84. KWAN P., ARZIMANOGLOU A., BERG A.T. et al. : Definition of drug resistant epilepsy : Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, *Epilepsia*, 2010, 51, 6, 1069-1077.
85. KWAN P., BRODIE M.J. : Early identification of refractory epilepsy, *New England Journal of Medicine,* 2000, 342, 314-319.
86. LADINO L.D., HERANDEZ-RONQUILLO L., TELLEZ-ZENTENO J.F. : Medical marijuana for epilepsy : a case series, *Can J Neurol Sci*, 2014, 41, 753-758.
87. LATTANZI S., BRIGO F., TRINKA E., ZACCARA G., CAGNETTI C., Del GIOVANE C., SILVESTRINI M. : Efficacy and Safety of Cannabidiol in Epilepsy : A Systematic Review and Meta-Analysis, *CNS Drugs*, 2018, 78, 17.
Doi : 10.1007/s40265-018-0992-5
88. LATTANZI S., BRIGO F., CAGNETTI C., TRINKA E., SILVESTRINI M. : Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome : A Systematic Review and Meta-Analysis, *CNS Drugs*, 2018, 32, (10), 905-916.
Doi : 10.1007/s40263-018-0558-9
89. LAUX L.C., BEBIN E.M., CHECKETTS D. et al. : Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome : expanded access program results, *Epilepsy Research,* 2019, 154, 13-20.
90. LEO A., RUSSO E., ELIA M. : Cannabidiol and epilepsy : Rationale and therapeutic potential, *Pharmacological Research*, 2016, 107, 85-92.
91. LIPPIELLO P., BALESTRINI S. CITRARO R., RUSSO E. et al. : From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We, *Current Pharmaceutical Design*, 2016, 22, 42, 6426-6433.
92. LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, *New England Journal of Medicine*, 2015, 373 1048-1058.
93. LORENZ R. : On the application of cannabis in paediatrics and epileptology, Neuro-endocrinology Letters, 2004, 25, 1-2, 40-44.
94. LUTZ B. : On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures, *Biochemical Pharmacology*, 2004, 68, 1691-1698.

95. MAA E., FIGI P. : The case for medical marijuana in epilepsy, *Epilepsia.* 2014, 55, 783-786.
96. MARSICANO G., GOODENOUGH S., MONORY K., HERMAN H. et al. : CB1 cannabinoid receptors and on-demand defense against excitotoxicity, *Science*, 2003, 302 (5642), 84-88.
97. MARTIN A.R., CONSROE P., SINGH V., MECHOULAM R. et al. : Structure-anticonvulsant activity relationships of cannabidiol analogs, *NIDA Research Monography*, 1987, 79, 48-58.
98. MATHERN G.W., BENINSIG L., NEHLIG A. : Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients : result of *Epilepsia's* survey, *Epilepsia,* 2015, 56, 1-6.
99. McCOY B., WANG L., ZAK M. et al. : A prospective open-label trial of a CBD / THC cannabis oil in Dravet syndrome, *Annals of Clinical and Translational Neurology*, 2018, 5, 1077-1088.
Doi : 10.1002/acn3.621
100. McLACHLAN R.S. : Marijuana : A Time-Honored but Untested Treatment for Epilepsy, *Canadian Journal of Neurological Sciences*, 2015, 42, 2, 88-91.
101. MELDRUM B.S., FARIELLO R.G., PUIL E.A. et al. : Delta 9-tetrahydrocannabinol and epilepsy in the photosensitive baboon Papio papio, *Epilepsia*, 1974, 15, 255-264.
102. MILLER I., PERRY M.S., SANETO R.P. et al. : Cannabidiol (CBD, 10 and 20 mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS) : Results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE2), Presented at « *71st American Academy of Neurology Annual Meeting »*, May 4-10, 2019, Philadelphia, PA, Emerging science abstract.
103. MITELPUNKT A., KRAMER U., HAUSMAN KEDEMM. et al. : The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: a phase II, open-label, single-center study, *Epilepsy & Behavior,* 2019, 98, 233-237.
104. MONORY K, MASSA F., EGERTOVA M., EDER M. et al. : The endocannabinoid system controls key epileptogenic circuits in the hippocampus, *Neuron*, 2006, 51, 4, 455-466.
105. MORTATI K., DWORETZKY B., DEVINSKY O. : Marijuana : An Effective Antiepileptic Treatment in Partial Epilepsy ? A Case Report and Review of the Literature, *Reviews in Neurological Diseases*, 2007, 4, 2, 103-106.
106. NAIDOO V., NIKAS S.P., KARANIAN D.A., WOOD J.T. et al. : A new generation fatty acid amide hydrolase inhibitor protects against kaiante-induced excitotoxicity, *Journal of Molecular Neuroscience*, 2011, 43, 3, 493-502.
107. NAIDOO V., KARANIAN D.A., VADIVEL S.K., LOCKLEAR J.R. et al. : Equipotent inhibition of fatty acid amide hydrolase and monocylglycerol lipase – Dual targets of the endocannabinoid system to protects against seizure pathology, *Neurotherapeutics*, 2012.
108. NEALE M. : Efficacy and safety of cannabis for treating children with refractory epilepsy, *Nurs Child Young People*, 2017, 29, 7, 32-37.
109. O'BRIEN T., BERKOVIC S.F., FRENCH J. et al. : Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults, Presented at : *American*

Epilepsy Society Annual Meeting, Washington, DC, December 1-5, 2017, Poster 2.428.
110. O'BRIEN T., BERKOVIC S.F., FRENCH J. et al. : Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults, Presented at « *American Epilepsy Society Annual Meeting »*, New Orleans, LA, November 30-December 4, 2018, Poster.
111. O'CONNEL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, *Epilepsy & Behavior*, 2016, 8 p.
112. OHRI A., DOUGHERTY M. : Exploring the Use of Cannabidiol in Epilepsy Management, *Practical Neurology*, 2016, July/August, 48-50.
113. OLDHAM M., SULLIVAN J., SINGHAL N., TILTON N., CILIO M. : Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsie, in « Procedings of the American Epilepsy Society Annual Meeting, 2015, December 4-8, Philadelphia, P.A., Abstr 2.296, *American Epilepsy Society*, Chicago, Il.
114. O'SHAUGHNESSY W.B. : On the preparations of the Indian hemp, or gunjah : *Cannabis indica* their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases, *Provincial Medical Journal and Retrospect of Medical Science,* 1843, 5, 363-369.
115. OSTENDORF A.P., NG Y.T. : Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions, *Neuropsychiatric Disease and Treatment,* 2017, 13, 1131-1140
116. PATEL A. : Real-World Approaches to Cannabinoids in Pediatric-Onset Epilepsy : What Do the Data Tell Us ?, *Medscape Education Neurology & Neurosurgery,* 2019.
www.medscape.org/viewarticle/922715
117. PATI S., ALEXOPOULOS A.V. : Pharmacoresistant epilepsy : From pathogenesis to current and emerging therapies, *Cleveland Clinic Journal of Medicine*, 2010, 77, 7, 457.
118. PATRA P.H., BARKER-HALISKI M, WHITE H.S., WHALLEY B.J., GLYN S., SANDHU H., JONES N., BAZELOT M., WILLIAMS C.M., McNEISH A.J. : Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models, *Epilepsia*, 2018, 1-12.
119. Doi : 10.1111/epi.14629
120. PIETRAFUSA N., FERRETTI A., TRIVISANO M. et al. : Purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy, *Paediatric Drugs,* 2019, 21, 283-290.
Doi :10.1007/s40272-019-00341-x
121. PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, *Epilepsy & Behavior*, 2013, 29, 3, 574-577.
122. PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, *Epilepsy & Behavior*, 2015, 45, 49-52.
123. RAJARAMAN R.R., SANKAR R., HUSSAIN S.A. : Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus, *Epilepsy & Behavior Case Reports*, 2018, 10, 141-144.
Doi : 10.1016/j.ebcr.2018.07.004

124. REDDY D.S., GOLUB V.M. : The Pharmacological Basis of Cannabis Therapy for Epilepsy, *J Pharmacol Exp Ther*, 2016, 357, 1, 45-55.
125. REDDY D.S. : The Utility of Cannabidiol in the Treatment of Refractory Epilepsy, *Clin Pharmacol Ther*, 2017, 101, 2, 182-184.
126. REGESTA G., TANGANELLI P. : Clinical aspects and biological bases of drug-resistant epilepsies, *Epilepsy Research*, 1999, 34, 2, 109-122.
127. REYNOLDS J.R. : On the therapeutical uses and toxic effects of *Cannabis indica*, *Lancet,* 1890, 135, 637-638.
128. RHO J.M., WHITE H.S. : Brief history of anti-seizure drug development. *Epilepsia Open,* 2018, 3, 114-119.
129. RIJCKEVORSEL K. : Treatment of Lennox-Gastaut syndrome : overview and recent findings, *Neuropsychiatric Disease and Treatment,* 2008, 1001.
130. ROSENBERG E.C., TSIEN RW, WHALLEY B.J., DEVINSKY O. : Cannabinoids and Epilepsy, *Neurotherapeutics*, 2015, 18, 747-768. (Cochrane Review)
131. ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, *Epilepsia*, 2017, 1-5.
132. ROSENBERG E.C., PATRA P.H., WHALLEY B.J. : Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection, *Epilepsy & Behavior*, 2017, 70, (Pt B), 319-327. Doi : 10.1016/j.yebeh.2016.11.006
133. RUSSO E.B. : Cannabis and epilepsy : An ancient treatment returns to the fore, *Epilepsy & Behavior*, 2016, 6 p.
134. SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, *Pediatric Neurology*, 2015, 52, 5, 544-547.
135. SANDS T.T., RAHDARI S., OLDHAM M.S., NUNES E.C., TILTON N., CILIO M.R. : Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy : Results from an Expanded Access Program in the US, *CNS Drugs*, 2018, 14 p.
Doi : 10.1007/s40263-018-0589-2
136. SHAW J. : On the use of the *Cannabis indica* (or Indian hemp)-1st-in tetanus-2nd-in hydrophobia-3rd-in cholera-with remarks on its effects, *Madras Quaterly Medical Journal,* 1843, 5, 74-80.
137. SOMMERVILLE K., Van LANDINGHAM K., HILL T., JONES N., PATEL A., GRAY R. : Cannabidivarin, Presented at : EILAT XIII, Madrid, Spain, June 26-29, 2016.
138. SURAEV A.S., TODD L., BOWEN M.T., ALLSOP D.J. et al. : An Australian nation wide survey on medicinal cannabis use for epilepsy : History of antiepileptic drug treatment predicts medicinal cannabis use, *Epilepsy & Behavior*, 2017, 7 p.
139. SURAEV A.S., LINTZERIS N., STUART J. et al. : Composition and use of cannabis extracts for childhood epilepsy in the Australian community, *Science Reports,* 2018, 8.
140. SZAFLARSKI J.P., BEBIN E.M. : Cannabis, cannabidiol and epilepsy – From receptors to clinical response, *Epilepsy & Behavior*, 2014, 41, 277-282.
141. SZAFLARSKI J.P., BEBIN E.M., COMI A.M., PATEL A.D. et al. : Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies : Expanded access program results, *Epilepsia*, 2018, 1-9.

142. SZAFLARSKI J.P., BEBIN E.M., CUTTER G., DeWOLF J. et al. : Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study, *Epilepsy & Behavior,* 2018. Doi : 10.1016/j.yebeh.2018.07.020.
143. SZAFLARSKI J.P. : Drug-drug interaction (DDI) studies with coadministration of cannabidiol (CBD) and clobazam (CLB), valproate (VPA), stiripentol (STP) or midazolam (MDZ) in healthy volunteers (HVTs) and adults with epilepsy, Presented at « *71st American Academy of Neurology Annual Meeting* », May 4-10, 2019, Philadelphia, PA, S3.003.
144. TANG R., FANG F. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, Comment, *New England Journal of Medicine,* 2017, 377, 7, 699.
145. THIELE E.A., MARSH E.D., FRENCH J.A. et al. – GWPCARE4 Study Group : Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4) : a randomised, double-blind, placebo-controlled phase 3 trial, *The Lancet,* 2018, 391, 1085-1096.
146. THIELE E.A., WONG M. : Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex : a randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6), Presented at « *American Epilepsy Society meeting 2019* », December 6-10, 2019, Baltimore, Maryland, Abstract 1.293.
147. TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, *Epilepsia*, 2017, 58, 1, 123-127.
148. TREMBLY B., SHERMAN M. : Double –blind clinical study of cannabidiol as a secondary anticonvulsant, in « *Marijuana'90 International Conference on Cannabis and Cannabinoids* », 1990.
149. TURKANIS S.A., SMILEY K.A., BORYS H.K., OLSEN D.M., KARLER R. : An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats, *Epilepsia*, 1979, 20, 4, 351-363.
150. TURNER A.L. : Cannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications, *Practical Neurology*, 2018, 31-35.
151. TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, *Seizure*, 2016, 35, 41-44.
152. UPADHYA D., CASTRO O.W., UPADHYA R., SHETTY A.K. : Prospects of cannabidiol for easing Status Epilepticus-Induced Epileptogenesis and related Comorbidities, *Molecular Neurobiology*, 25 January 2018. Doi : 10.1007/s12035-018-0898-y
153. VANDREY R., RABER J.C., RABER M.E. : Cannabinoid dose and label accuracy in edible medical cannabis products, *JAMA,* 2015, 313, 2491-2493.
154. Van LANDINGHAM K., JONES N., GRAY R. et al. : Cannabidivarin : pre-clinical and initial clinical data on seizures and future development, Presented at : EILAT XIV, Madrid Spain, May 13-16, 2018.
155. Van STRATEN A.F., NG Y.T. : Update on the management of Lennox-Gastaut syndrome, *Pediatric Neurology,* 2012, 47, 153-161.
156. VASHI N., JUSTICE M.J. : Treating Rett syndrome : from mouse models to human therapies, *Mammalian Genome,* 2019, 30, 90-110.
157. VEZYROGLOU K., CROSS J.H. : Targeted Treatment in Childhood Epilepsy Syndromes, *Epilepsy, Current treatment Options Neurology*, 2016, 18, 29, 12 pp.

158. VIGLI D., COSENTINO L, RAGGI C. et al. : Chronic treatment with the phytocannabinoid cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome, *Neuropharmacology,* 2018, 140, 121-129.
159. WADA J.A., OSAWA T., CORCORAN M.E. : Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons papio papio, *Epilepsia*, 1975, 16, 439-448.
160. WALLACE M.J., BLAIRR.E., FALENSKI K.W., MARTIN B.R., DeLORENZO R.J. : The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy, *J Pharm Exp Ther*, 2003, 307, 129-137.
161. WANG G.S., BOURNE D.W.A., KLAWITTER J., SEMPIO C., CHAPMAN K., KNUPP K., WEMPE M.F., BORGELT L. et al. : disposition orale Cannabidiol-riches extraits de cannabis chez les enfants atteints d'épilepsie, *Clinical Pharamacokinetics*, 2020.
Doi : 10.1007/s40262-020-00869-z
162. WELTY et al. : Cannabidiol : promise and pitfalls, *Epilepsy Curr*, 2014, 14, 5, 250-252.
163. WHALLEY B.J., LIN H., BELML L., HILL T., PATEL A., GRAY R.A., ROBERTS C.E., DEVINSKY O., BAZELOT M., WILLIAMS C.M., STEPHENS G.J. : species-specific susceptibility to cannabis-induced convulsions, *British Journal of Pharmacology*, 2018, 1-18.
Doi : 10.1111/bph.14165
164. WHELESS J.W., DLUGOS D., MILLER I., OH D.A., PARIKH N., PHILLIPS S., RENFROE J.B., ROBERTS C.M., SAEED I., SPARAGANA S.P., YU J., CILIO M.R., on behalf of the INS011-14-029 Study Investigators, *CNS Drugs,* 2019, 1-12.
Doi : 10.1007/s40263-019-00624-4
165. WIRRELL E.C., LAUX L., DONNER E. et al. : Optimizing the diagnosis and management of Dravet syndrome : recommendations from a North American Consensus panel, *Pediatric Neurology,* 2017, 68, 18-34.e13.
166. WONG S.S., WILENS T.E. : Medical Cannabinoids in Children and Adolescents : A Systematic Review, *Pediatric*, 2017, 140, 16 p.

US Food and Drug Administration. FDA and cannabis : research and drug approval process. December 6, 2019.
Available at : https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process

US Food and Drug Administration **:** What you need to know (and what we're working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. November 25, 2019.
Available at : https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis

EPIDIOLEX® (cannabidiol oral solution) [prescribing information], Approved 2018. Carlsbad, CA, Greenwich Biosciences Inc., Updated December 2018.

Institute of Medicine : *Epilepsy Across the Spectrum : Promoting Health and Understanding*, Washington, DC, The National Academies Press, 2012.
https://doi.org/10.17226/13379

EPIDIOLEX® – Epilepsie de l'enfant

Essais cliniques : DEVINSKY et al. (2014), DEVINSKY et al. (2016), DEVINSKY et al. (2017).
GW Pharmaceutical, NCT02091375. (2015)
- Epidiolex® : 98 % CBD oil.
- Dose 25 à 50 mg/kg/jour.

- DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, *Epilepsia*, 2014, 55, 6, 791-802.
- DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, *Lancet Neurology*, 2015.
- DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug – Resistant Seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 21, 2011-2020.
- LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, *New England Journal of Medicine*, 2015, 373 1048-1058.
- O'CONNEL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, *Epilepsy & Behavior*, 2016, 8 p.
- ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, *Epilepsia*, 2017, 1-5.
- TANG R., FANG F. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, Comment, *New England Journal of Medicine,* 2017, 377, 7, 699.

- GW Pharmaceuticals Initiate second Phase 3 Pivotal Study of Epidiolex (CBD) i Lennox Gastaut Syndrome. *Press Release*, June 11, 2015.

https://www.gwpharm.com/epilepsy-patients-caregivers/clinicians-researchers
https://www.cannabis-medicinale.fr/epidiolex/

- GW Pharmaceuticals and the Government of New South Wales announce a strategic agreement to study epidiolex and CBDV in a clinical trial and research program for children with epilepsy, *GW Pharma Press Release*, October 17, 2015

http://www.gwpharm.com/GWPandGovNewSouthWales271015.aspx.

- USA : Use of Cannabinoids in the treatment of Epilepsy, 2015, *Patent Application Pub : US 2016/0166515 A1*, GW Pharma Limited, Cambridge, (GB) : GUY G., WRIGHT S., MEAD A., DEVINSKY O. (June 2016)

Autres essais cliniques :

Essai clinique : TREMBLY B. et SHERMAN M. (**1990**)

- « no differences between CBD and Placebo »
- faible dose CBD (100 mg once daily)

❖ TREMBLY et SHERMAN : Double –blind clinical study of cannabidiol as a secondary anticonvulsant, in « *Marijuana'90 International Conference on Cannabis and Cannabinoids* », 8-11 Juillet 1990, Kolymbari, Crète, IACM.

Essai clinique : *Open study, Faculté de Médecine, Università « La Sapienza », 00100 Rome, Italy*, (**2002)** :

- CBD in a 2,5% corn oily

❖ PELLICCIA A., GRASSI G., ROMANO A., CROCCHIALO P. : Treatment with CBD in oily solution of drug-resistant paediatric epilepsies, *2005 Congress on Cannabis and the Cannabinoids, Leiden, The Nederlands, Meeting Abstract, IACM*, p 14.

Essai clinique : LORENZ (**2004**)

- Dronabinol
- Case series (Neurodegenerative diseases, mitochrondopathy, post-hypoxic state, epilepsy)

❖ LORENZ R. : On the application of cannabis in paediatrics and epileptology, *Neuroendocrinol Lett*, 2004, 25, 1-2, 40-44.

Essai clinique : HESS et al. (**2011**)

- étude de l'efficacité du CBD dans le cadre des épilepsies résistantes dans la Sclérose Tubéreuse Complexe (TSC)

❖ HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, *Epilepsy & Behavior*, 2012, 25, 4, 563-566.

Essai clinique : GEDDE et MAA (**2013**)

- Realm Oil (extract of 16 :1 CBD cannabis plant)
- 4 à 12 mg/kg /jour

Essai clinique : PORTER et JACOBSEN (**2013**) : étude faite par des parents d'enfants présentant des épilepsies résistantes et prenant régulièrement du cannabis

- CBD-enriched cannabis product
- 19 patients, 16 répondeurs

❖ PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, *Epilepsy & Behavior*, 2013, 29, 3, 574-577.

Essai clinique : FRIEDMAN et al. (**2014**)
- CBD (Epidiolex® 25 mg/kg / jour) + clobazam (17 patients) + group control clobazam (16 patients)
- 7/17 patients on pu obtenir une réduction de leur dose de clobazam

❖ FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand acess program, *Annual Meeting of the American Epilepsy Society, Seattle, December 5-9*, 2014, Abstract.

Essai clinique : SAADE et JOSHI (**2015**)
- MMSI
- CBD Case Report

❖ SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, *Pediatr Neurol*, 2015, 52, 5, 544-547.

Essai clinique : HUSSAIN et al. (**2015**)
- CBD-enriched OCE
- Parent survey

❖ HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, *Epilepsy & Behaviour*, 2015, 47, 138-141.

Essai clinique : PRESS et al. (**2015**)
- OCE
- Retrospective chart review

❖ PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, *Epilepsy & Behavior*, 2015, 45, 49-52.

Essai clinique : TZADOK et al. (**2016**)
- CBD-enriched OCE
- Retrospective chart review

❖ TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, *Seizure*, 2016, 35, 41-44.

Essai clinique : TREAT et al. (**2017**)
- OCE
- Retrospective chart review

❖ TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, *Epilepsia*, 2017, 58, 1, 123-127.

Essai clinique : KAPLAN et al. (**2017**)
- CBD
- Open-label trial

❖ KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, *Pediatr Neurol,* 2017, 71, 18-23.

Essai clinique : GOFSHTEYN et al. (**2017**)
- CBD
- Open-label trial

❖ GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, *Journal of Child Neurology*, 2016.